832-497-2220 [email protected]

Submitted Projects

Cell and Gene Therapy Challenge

New Vaccine Challenge

COPD/Asthma

CNS

AMD 

Diabetes

Pediatric Drug

Pediatric Drug

Project ID: PED101

Category: Pediatric Drug

Keyword: Novel bioactive lipid compounds

Project/Product Summary:

Project PED101 develops new medicines for unmet needs in dermatological diseases. The compounds under development are based on a novel bioactive lipid platform. These molecules are crucial to the pathways of several conditions including skin disorders such as atopic dermatitis (AD). The Company’s lead compound is being explored clinically as both a topical cream for mild to moderate AD (Phase 3) and separately as an oral capsule in moderate to severe AD (Phase 2b). DS holds multiple patents and pending applications protecting the product and its clinical uses.

Indications: Atopic Dermatitis in

Children and Adolescents

Stage: Clinical Phase II/Phase III

Partnering Objectives: Fundraisingd US$48 million for Phase III of the experiment

Country: Ireland

Project ID: PED102

Category: Pediatric Drug

Keyword: Glycopyrronium Bromide Liquid

Project/Product Summary:

The company develops product Glycopyrronium Bromide is proven to be effective and well-tolerated in treating severe hypersalivation in children and adolescents with cerebral palsy or other neurological conditions; it is available in a liquid formulation to provide maximal dosing flexibility and tolerability. Licensed indications include: Symptomatic treatment of severe sialorrhoea (chronic pathological drooling) in children and adolescents aged 3 years and older with chronic neurological disorders

Indications: Excessive saliva

production

Stage: public listed

Partnering Objectives: Commercial cooperation, product Licensing
Country: UK

Project ID: PED103

Category: Pediatric Drug

Keyword: SVLP technology
Project/Product Summary:
Project PED103 is developing next-generation synthetic vaccines to prevent infectious diseases and treat chronic diseases. The company has two proprietary technologies: Synthetic Antigen Mimetics (SAMs) and a Synthetic Virus-Like Particle (SVLP) platform to deliver and present SAMS to the immune system. Manufactured synthetically, these vaccines are inexpensive, easy-to-produce, modular, and customisable. They do not require the addition of adjuvants. Based on strong preclinical data and a validated target, the lead asset, V-306, is about to enter Phase 1 in RSV. Success in the project will provide a proof-of-concept to leverage the promising pipeline in infectious diseases and oncology. Virometix is seeking a licensing partner for China and/or a Chinese strategic investor for a co-development agreement.
Indications: Infectious diseases, respiratory and tumor diseases
Stage: Preclinical
Partnering Objectives: Fundraising, business cooperation
Country: Switzerland
Cell and Gene Therapy Challenge

Project ID: CGT100

Category: Cell and Gene Therapy Challenge

Keywords: ACE2 Inhibitor

Project/Product Summary:

Our apelin therapy provides the evolutionary solution to inhibit viral replication and downstream ACE2 downregulation at the receptor level.

Indications: Heart failure, diabetes, pulmonary hypertension

Stage: IND

Partnering Objective: Fundraising, Co-development

Country: USA

Project ID: CGT101

Category: Cell and Gene Therapy Challenge

Keywords: Tumor infiltrating lymphocyte immunotherapy (TIL therapy)
Project/Product Summary:
Project relies on the Cancer Research Center of the Champalimaud Foundation of Portugal as the European clinical base. The introduction of immunological medical technology to the country, the first batch of European top tumor immunotherapy technologies, including tumor infiltrating T lymphocyte therapy, virus infection T cell therapy, etc.
Indications: Cancer, Tumor
Stage: Research
Partnering Objective: Fundraising, Co-development
Country: Portugal/China

Project ID: CGT102

Category: Cell and Gene Therapy Challenge

Keywords: Brain repair technology
Project/Product Summary:
Project is developing a revolutionary brain repair technology for neurological diseases. Our proprietary and patented in vivo cell conversion technology regenerates neurons from glial cells in diseased central nervous system.
Company is developing two platform technologies, gene therapy and small molecule therapy, including 4 gene therapies and one small molecule in the pipeline, to treat a variety of neurological disorders including stroke, Alzheimer’s disease, ALS, spinal cord injury, Parkinson’s disease, and Huntington’s disease.
Indications: Stroke, Alzheimer’s disease, ALS, spinal cord injury, Parkinson’s disease and Huntington’s disease.
Stage: Research
Partnering Objective: Fundraising, Co-development, Commercialization Licensing
Country: USA
Project ID: CGT103

Category: Cell and Gene Therapy Challenge

Keywords: T cell immunotherapy
Project/Product Summary:
The company is a fully-integrated biotechnology research, medical and wellness services group of companies. Company’s business focus is on the perception that the use of precision and preventive medicine as therapeutic entities will drive one of the next most important phases in medicine and wellness. Today, The company in Malaysia has evolved into a modern, preferred Asia Pacific destination for medical tourism providing specialized boutique precision and preventive medical and wellness services for today’s modern consumer seeking to look and feel good, aesthetically and medically for posterity. Driven by its Head Office in Malaysia, company’s core service centres are the ALPS Medical Centre in the heart of Kuala Lumpur’s Central Business District and a Wellness and Anti-Aging Centre in the cool internationally renowned highlands resort of Genting Highlands. They cater to local and international clientele which has been growing significantly in recent years due to the quality of services supported by a good marketing network locally and overseas taking advantage of the growth of Malaysia as a medical tourism venue. Compnay has established the first commercialized Human Genomic Lab (MyGenome) located at ALPS Medical Centre, Malaysia.
Indications: Cancer and neurological diseases
Stage: Clinical Phase I/II
Partnering Objective: Pre-IPO Fundraising
Country: Malaysia
Project ID: CGT104

Category: Cell and Gene Therapy Challenge

Keywords: Bioartificial liver
Project/Product Summary:
China has a large population that is affected by liver diseases. There are about 1 million new cases of liver failure each year. The 28-day mortality is as high as 50% in patients with acute liver failure. Project has developed a bioartificial liver that is an in vitro liver function support system, which can substitute hepatic function in a short period to prevent the manifestations of liver failure, promote the recovery of native liver function in patients with liver failure to avoid liver transplantation, or bridge patients to liver transplantation. By using such technology, the project has finished pilot studies with more than 10 liver failure patients in China. Results showed reliable safety and outstanding clinical efficacy with >90% long-term survival rate.
Indications: Liver Disease
Stage: Preclinical
Partnering Objective: Fundraising, Licensing
Country: China
New Vaccine Challenge
Project ID: VAX100
Category: New Vaccine Challenge
Keywords: COVID-19 intranasal vaccine
Project/Product Summary:
A biotechnology company from the United States, just announced the COVID-19 intranasal vaccine project on February 28. The vaccine uses company’s proprietary technology, and the design and synthesis of the vaccine has been completed, and it is being promoted in animal testing and production. Clinical testing of the vaccine can start as early as August. This new intranasal vaccine is based on the same platform vaccine technology as company’s influenza vaccine candidate NasoVAX and aims to provide systemic immunity after a single intranasal administration. A recent phase 2 clinical study conducted with NasoVAX emphasized that intranasal vaccine delivery can stimulate a durable and broad immune response against influenza viruses.
Indications: epidemic viruses
Stage: Pre-clinical
Partnering Objective: Fundraising, Licensing
Country: USA
Project ID: VAX101
Category: New Vaccine Challenge
Keywords: Polyoxidonium immunomodulator
Project/Product Summary:
Leading Russian vaccine manufacturer, proposes an additional tool to fight Wuhan coronavirus outbreak: Polyoxidonium immune modulator, PO for short. PO is currently used as a standalone drug in infectious diseases since 1996.
According to limited available data two thirds of 2019-nCoV patients have lymphopenia and many of those who died from the virus had co-morbidities or were >50 years old. From previous coronavirus epidemics we know that immunocompromised individuals are more likely to get infected and die from the disease. Therefore therapies that enhance immune function may have effect in decreasing mortality and severity of disease. PO was extensively studied in Russia as a single agent immune modulator in patients with infectious diseases in multiple trials. Results of these studies make PO in our view a very promising molecule for treating 2019-nCoV patients.
In several clinical trials in cancer patients receiving chemotherapy PO administration led to significant increase in blood CD4 and CD8 cell counts. In HIV infected patients with pneumonia PO administration in combination with antibiotics led to drastic decrease of duration of symptoms in comparison with antibiotics alone. CD4 counts in these patients were also increased due to PO action. This effect was repeated in two-year old pneumonia patients (young children have underdeveloped immunity). In patients with primary immunodeficiency PO shortened the duration of infection disease episodes and increased the duration of remission. The inclusion of PO in the treatment of patients with acute pancreatitis reduced mortality by 2 times. It is worth mentioning that safety of PO was proven in more than 20 clinical trials and were conducted in Russia and in other countries, including Slovakia. In all clinical studies and for many years of use in clinical practice Polyoxidonium showed a good safety profile.
We believe that PO should be studied as an immune enhancing agent in 2019-nCoV patients due to its effect on lymphocyte count and on the duration of pneumonia in immunocompromised patients. Therefore therapies that enhance immune function may have effect in decreasing mortality and severity of disease in 2019-nCoV patients.
We suggest to organize collaborative study with Chinese virologists currently fighting nCoV outbreak.
Indications: Covid-19 and other epidemic viruses
Stage: On the market
Partnering Objective: Commercialization Licensing
Country: Russia
Project ID: VAX102
Category: New Vaccine Challenge
Keywords: Hepatitis B functional cure vaccine
Project/Product Summary:
The project is developing VVX001, a therapeutic vaccine for chronic hepatitis B with the goal of achieving a functional cure. The product is differentiated by specifically eliciting antibodies targeted to the attachment site of the virus through the PreS1 component of the large surface antigen. It has been demonstrated that antisera from immunized human subjects prevent infection of cells by the hepatitis B virus (neutralizing antibodies). In addition VVX001 stimulates PreS specific CD4- and CD8 cells, which in concert with ADCC and ADCP triggered by the antibodies will contribute to elimination of infected hepatocytes and thereby removal of cccDNA from the liver of the patient. The product is currently in a phase I/II trial, where its effect is analyzed in vaccination naive subjects, subjects who failed to mount a protective immune response to conventional vaccination and patients with chronic
hepatitis B on long term treatment with nucleotide/nucleoside antivirals. Readout of this trial is expected in 2021. The product is available for outlicensing or co-development. We are also seeking funding for worldwide clinical development.”
Indications: Chronic hepatitis B
Stage: Phase II
Partnering Objective: Co-development, Licensing
Country: Austria
COPD/Asthma
Project ID: COPD100
Category: COPD/Asthma
Keywords: re-open the collapsed small airways
Project/Product Summary:
Project has developed a new device for the treatment of COPD.  For the last 50 years, there have been no significant advances in COPD treatment.  Standard of care treatment for COPD is primarily by inhaled bronchodilators. However, these drugs only target the upper airways, and much of COPD is caused by the collapse of small airways.
The company’s Pulsehaler™ technology is the first and only treatment to directly re-open the collapsed small airways of COPD patients, thereby reducing breathlessness and improving patient’s ability to walk. The Pulsehaler™ technology produces unique multi-frequency, air pressure pulses which are carried into the lungs, gently prying open the airways, lowering the viscosity of mucus that could re-plug the airway, and stenting the airway open to allow the airway clearance mechanisms to function properly. The technology was clinically proven in a double blind controlled study, and published in the peer reviewed Journal of COPD. Our technology is protected by 6 patent families, with 15 issued patents and 9 additional pending patents.
The company’s technology pipeline also includes patented designs for improving delivery of inhaled drugs. This technology was clinically proven to deliver drugs more than 200% better than traditional nebulizers, with significant improvements in lung function. We have begun initial discussions with Pharma companies to partner in the development of Best-in-Class inhaled therapies, including COPD, Cystic Fibrosis, Asthma, Idiopathic Pulmonary Fibrosis, and Pulmonary Arterial Hypertension.
Indications: COPD, Cystic Fibrosis, Asthma, Idiopathic Pulmonary Fibrosis, and Pulmonary Arterial Hypertension.
Stage: NDA
Partnering Objective: Series B fundraising $ 10 Million, Licensing, Joint-venture
Country: Israel
CNS
Project ID: CNS100
Category: CNS
Keywords: Degenerative neurological disease drugs
Project/Product Summary:
This project focuses on drug development for Parkinson’s disease (PD), Alzheimer’s disease (AD) and other related diseases such as type 2 diabetes (T2D). The team uses a new drug screening technology to solve the biological stress (Biochemical Stress) problem in these diseases from the fundamental biological mechanism-including Oxidative Stress, Glyoxal Stress and Protein Aggregation stress and many more. Cantabio is now focusing on the development of new drugs in the small molecule chaperone category that will soon enter clinical testing. Cantabio’s core technical advantage in the global sense lies in its research and development capabilities for Intrinsically Disordered Proteins such as Tau and new protein targets such as DJ-1. DJ-1’s multifunctional characteristics have a systemic effect on biological stress.
Indications: Parkinson’s disease (PD), Alzheimer’s disease (AD) and other neurodegenerative diseases
Stage: Clinical Phase I
Partnering Objective: Fundraising, Licensing
Country: USA
Project ID: CNS101
Category: CNS
Keywords: Degenerative neurological disease drugs
Project/Product Summary:
Company’s candidate medicine Posiphen® targets early stage Parkinson’s Disease as well as Alzheimer’s Disease and may stop or slow the progression of those diseases. Posiphen® reduces levels of amyloid precursor protein (APP), tau and α-Synuclein (aSYN), three proteins that can turn toxic and precipitate the onset of neurodegeneration.
Posiphen® inhibits APP, tau and aSYN in tissue culture cells, mice as well as in humans. Posiphen® also shows promise in Huntington’s disease, Down Syndrome, Traumatic Brain Injury, and Post Operative Cognitive Decline. So far three clinical studies have been conducted with Posiphen®.
Indications: Parkinson’s disease (PD), Alzheimer’s disease (AD) and other neurodegenerative diseases
Stage: Clinical Phase I
Partnering Objective: Fundraising, Licensing
Country: USA

Dia

Project ID: DIA100
Category: Diabetes
Keywords: Insulin drugs
Project/Product Summary:
Project employs its proprietary excipient library, BioChaperone®, to unlock new clinical benefits of already-approved treatments in the fields of diabetes and metabolism
Indications: Diabetes and other metabolic diseases
Stage: Clinical Phase III
Partnering Objective: Joint development, Commercial license
Country: France
Project ID: DIA101
Category: Diabetes
Keywords: Protease activator
Project/Product Summary:
Project employs its proprietary excipient library, BioChaperone®, to unlock new clinical benefits of already-approved treatments in the fields of diabetes and metabolism
Indications: Diabetes and other metabolic diseases
Stage: Clinical Phase III
Partnering Objective: Joint development, Commercial license
Country: France